SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksUniphar Regulatory News (UPR)

Share Price Information for Uniphar (UPR)

Share Price is delayed by 15 minutes
Get Live Data
416.00    2.00 (0.48%)
Bid:
414.00
Ask:
418.00
Spread: 4.00 (0.966%)
Market Cap: £1.08b
UPR Live PriceLast checked at - London Stock Exchange

Intraday Uniphar Share Chart

Directorate Change

21 Apr 2020 07:00

RNS Number : 2673K
Uniphar PLC
21 April 2020
 

 

 

 

Director Resignation

 

 

Dublin, London | 21 April 2020

 

 

Uniphar plc (the "Company") wishes to announce that John Holly has informed the Board that he will not put himself forward for re-election at the forthcoming AGM following ten years' service on the Board and the successful IPO in July 2019. His resignation will take effect immediately following the Company's AGM.

 

 

Maurice Pratt, Chairman of Uniphar plc, commented:

"I would like to personally thank John for the very significant contribution he has made as a Board member over the past decade, and to wish him well in the future."

--- ENDS ---

 

For further details contact:

 

Uniphar

 

Brian O'Shaughnessy

Group Director of Corporate Development

 

+353 (0) 1 428 7777

 

 

investor.relations@Uniphar.ie

 

 

Davy

(Nominated Adviser and Euronext Growth Adviser)

 

Fergal Meegan

Barry Murphy

Tom Tynan

 

+353 (0) 1 679 6363

 

About Uniphar plc

 

Headquartered in Dublin, Ireland, Uniphar plc is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,200, the Group is active in Ireland, the UK, the Benelux, the Nordics and the US.

 

The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth and profitability.

 

Commercial & Clinical 

In Commercial & Clinical the Group provides sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Active in Ireland, the UK, the Benelux and the Nordics, the Group is growing with clients to provide pan-European solutions. Uniphar have built a fully integrated multi-channel solution that is supported by highly experienced, clinically trained teams to deliver exceptional outcomes for all clients.

 

Product Access 

In Product Access the Group is growing two distinct service offerings: 1) "On-Demand Access", which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions to more than 160 markets globally.

 

Supply Chain & Retail 

Uniphar is an established market leader in Ireland with c50% supply chain market share supported by a network of 287 owned, franchised and symbol group pharmacies. The business supports the diverse customer base through the provision of strong service levels coupled with innovative commercial initiatives. Supply Chain & Retail is an Irish only business for the Group, although the assets and infrastructure are utilised for the benefit of the growth divisions.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAEAELEAFEEEAA
Date   Source Headline
2nd Jun 20267:00 amRNSChange of Nominated Adviser
15th May 20267:00 amRNSDirector/PDMR Shareholding
7th May 20263:32 pmRNSAGM Results
7th May 20267:00 amRNSAGM Statement
30th Apr 20265:41 pmRNSHolding(s) in Company
29th Apr 20267:00 amRNSHolding(s) in Company
28th Apr 20265:38 pmRNSHolding(s) in Company
13th Apr 20267:00 amRNSExecutive Restricted Share Plan Dealings
7th Apr 202611:07 amRNSHolding(s) in Company
2nd Apr 202611:12 amRNSHolding(s) in Company
1st Apr 20267:00 amRNSNotice of AGM & Annual Report
27th Mar 202612:00 pmRNSHolding(s) in Company
19th Mar 20262:44 pmRNSHolding(s) in Company
17th Mar 20263:35 pmRNSHolding(s) in Company
12th Mar 202611:59 amRNSHolding(s) in Company
10th Mar 20261:30 pmRNSHolding(s) in Company
25th Feb 20262:45 pmRNSHolding(s) in Company
25th Feb 20262:45 pmRNSHolding(s) in Company
24th Feb 20267:00 amRNS2025 Preliminary Results
29th Jan 202612:45 pmRNSHolding(s) in Company
27th Jan 20267:00 amRNSFull Year Trading Update and Notice of Results
6th Jan 20263:39 pmRNSHolding(s) in Company
17th Dec 20252:22 pmRNSHolding(s) in Company
16th Dec 202512:03 pmRNSHolding(s) in Company - Replacement
12th Dec 20251:15 pmRNSDirector/PDMR Shareholding
10th Dec 20253:40 pmRNSHolding(s) in Company
28th Nov 20252:14 pmRNSHolding(s) in Company
27th Nov 202512:01 pmRNSHolding(s) in Company
25th Nov 20257:00 amRNSHolding(s) in Company
13th Nov 20257:00 amRNSDirector/PDMR Shareholding
11th Nov 202512:06 pmRNSHolding(s) in Company
24th Oct 202511:59 amRNSHolding(s) in Company
2nd Sep 20257:00 amRNS2025 Interim Results
29th Jul 20257:00 amRNSHalf Year Trading Update and Notice of Results
12th Jun 20254:45 pmRNSHolding(s) in Company
27th May 20252:15 pmRNSHolding(s) in Company
12th May 20252:52 pmRNSDirector/PDMR Shareholding
8th May 20252:09 pmRNSAGM Results
8th May 20259:45 amRNSHolding(s) in Company
8th May 20257:00 amRNSAGM Statement
7th Apr 20254:34 pmRNSHolding(s) in Company
3rd Apr 20257:01 amRNSNotice of AGM & Annual Report
7th Mar 20257:00 amRNSTransaction in Own Shares
6th Mar 20254:10 pmRNSHolding(s) in Company
6th Mar 20257:00 amRNSTransaction in Own Shares
5th Mar 20252:30 pmRNSHolding(s) in Company
5th Mar 20252:30 pmRNSHolding(s) in Company
5th Mar 20257:00 amRNSTransaction in Own Shares
4th Mar 20257:00 amRNSTransaction in Own Shares
3rd Mar 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.